Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ENDRA Life Sciences Inc (NDRA)
NASDAQ:NDRA
RESEARCH TOOLSreports
ENDRA Life Sciences (NDRA) Stock Price & Analysis
583 Followers
NDRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.07 - $2.79
Previous Close$0.08
Volume2.93M
Average Volume (3M)20.95M
Market Cap
$5.61M
Enterprise Value$5.94M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$324.06K
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Aug 12, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding11,035,659
10 Day Avg. Volume48,791,478
30 Day Avg. Volume20,950,763
Standard Deviation0.35
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$8.00Price Target Upside9912.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
ENDRA Life Sciences News
PremiumCompany Announcements
ENDRA Life Sciences Announces Strategic Public Offering Deal
PremiumCompany Announcements
ENDRA Life Sciences Issues Financial Information Disclaimer
Bulls Say, Bears Say
Bulls Say
Financial PerformanceENDRA raised approximately $8 million through stock sales, ensuring enough cash reserves to fund operations until 2025.
Innovative TechnologyENDRA's Thermo Acoustic Enhanced UltraSound (TAEUS) platform allows clinicians to visualize human tissue composition, function, and temperature in ways previously possible only with CT and MRI, but at a fraction of the cost and at the point-of-care.
Market OpportunityThe launch of ENDRA's TAEUS application to measure liver fat presents a significant market opportunity, particularly for early detection and monitoring of Steatotic Liver Disease (SLD) and Non-Alcoholic Fatty Liver Disease (NAFLD).
Bears Say
Financial GuidanceManagement did not provide 2024 financial guidance.
Regulatory ApprovalThe FDA has requested for more information and ENDRA will meet with the FDA soon to discuss any new requirements or timeline to get approval.
RevenueENDRA is a late stage medical device development/early stage commercialization company so it generates no revenues.
---
Ownership Overview
0.95%
Insiders
0.14% Mutual Funds
0.11% Other Institutional Investors
98.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NDRA FAQ
What was ENDRA Life Sciences Inc’s price range in the past 12 months?
ENDRA Life Sciences Inc lowest stock price was $0.07 and its highest was $2.79 in the past 12 months.
What is ENDRA Life Sciences Inc’s market cap?
Currently, no data Available
When is ENDRA Life Sciences Inc’s upcoming earnings report date?
ENDRA Life Sciences Inc’s upcoming earnings report date is Aug 12, 2024 which is in 15 days.
How were ENDRA Life Sciences Inc’s earnings last quarter?
ENDRA Life Sciences Inc released its earnings results on May 14, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.01.
Is ENDRA Life Sciences Inc overvalued?
According to Wall Street analysts ENDRA Life Sciences Inc’s price is currently Undervalued.
Does ENDRA Life Sciences Inc pay dividends?
ENDRA Life Sciences Inc does not currently pay dividends.
What is ENDRA Life Sciences Inc’s EPS estimate?
ENDRA Life Sciences Inc’s EPS estimate is -$0.07.
How many shares outstanding does ENDRA Life Sciences Inc have?
ENDRA Life Sciences Inc has 70,273,315 shares outstanding.
What happened to ENDRA Life Sciences Inc’s price movement after its last earnings report?
ENDRA Life Sciences Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of ENDRA Life Sciences Inc?
Currently, no hedge funds are holding shares in NDRA
---
ENDRA Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (9912.52% Upside)
$8.00 (9912.52% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 7.7%
Last 30 Days ▲ 7.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.87%
12-Months-Change
Fundamentals
Return on Equity
-241.38%
Trailing 12-Months
Asset Growth
-23.96%
Trailing 12-Months
Company Description
ENDRA Life Sciences Inc
ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.
---
NDRA Earnings Call
Q1 2024
0:00 / 0:00
---
NDRA Stock 12 Month Forecast
Average Price Target
$8.00
▲(9912.52% Upside)
Technical Analysis
Best Analysts Covering NDRA
1 Year
1 Year Success Rate
0/8 ratings generated profit
1 Year Average Return
-75.13%
reiterated a buy rating 2 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -75.13% per trade.
---